9th International Science Congress (ISC-2019).  International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

5-Nitroimidazole derivatives: A scope of Modification for Medicinal chemists

Author Affiliations

  • 1Department of chemistry, H.N.B. Garhwal University, Srinagar Garhwal, Uttarakhand, INDIA
  • 2Department of Chemistry, University of Delhi, Delhi, INDIA

Res.J.chem.sci., Volume 3, Issue (7), Pages 104-113, July,18 (2013)

Abstract

The 5-nitroimidazole is an important class of imidazole based drugs. The 5-nitroimidazoles are a well-established group of protozoal and bactericidal agents but after discovery of imidazole drugs many protozoa and bacteria has developed resistance towards drugs in market. Due to this fact there is a need for medicinal chemists to work on this pharmacophore and develop new hybrid molecules which may give lead molecule for further studies. Many modifications have been done on 5-nitroimidazole nucleus and new hybrid molecules have been synthesized but still there is a huge scope of modification. The imidazole moiety exhibit wide range of biological activities. This article aims to review the work done in past few years, on 5-nitroimidazoles derivatives synthesis and activity of resulting hybrid molecules.

References

  1. Müller M., Mode of action of metronidazole on anaerobic bacteria and protozoa, Surgery, 93, 165–171 (1983)
  2. Upcroft J.A., Campbell R.W., Benakli K., Upcroft P. and Vanelle P., Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob. Agents Chemother., 43, 73–76 (1999)
  3. Jokipii A.M. and Jokipii L., Metronidazole, tinidazole, ornidazole and anaerobic infections of the middle ear, maxillary sinus and central nervous system, Scand. J. Infect. Dis. Suppl., 26, 123–129 (1981)
  4. Demirayak S., Karaburun A.C. and Kiraz N., Synthesis and antibacterial activities of some 1-[2-(substituted pyrrol-1-yl)ethyl]-2-methyl-5-nitroimidazole derivatives, Eur. J. Med. Chem., 34, 275–278 (1999)
  5. Walsh A.J., Davis M.L. and Fraser W., Solid phase synthesis of a metronidazole oligonucleotide conjugate,Molecules, 11, 486–495 (2006)
  6. Adams G.E., Redox, radiation and reductive bioactivation,Radiat. Res.,132, 129–139 (1992)
  7. Adams G.E. and Stratford I.J., Hypoxia-mediated nitroheterocyclic drugs in the radio- and chemotherapy of cancer, Biochem Pharmacol., 35, 71–76 (1986)
  8. Adams G.E. and Stratford I.J., Bioreductive drugs for cancer therapy: the search for tumor specificity, Int. J. Radiat. Oncol. Biol. Phys., 29, 231–238 (1994)
  9. Kapoor V.K., Chadha R., Venisetty P.K. and Prasanth S., Medicinal significance of nitroimidazoles: Some recent advances, J Sci Ind Res (India), 62, 659–665 (2003)
  10. Nagarajan K., Shankar R.G., Rajappa S., Shenoy S.T. and Costa-Pereira R., Nitroimidazoles XXI 2,3-dihydro-6nitroimidazo [2,1-b] oxazoles with anti-tubercular activity, Eur. J. Med. Chem., 24, 631–633 (1989)
  11. Gunay N.S., Capan G., Ulusoy N., Ergenc N., Otuk G. and Kaya D., 5-Nitroimidazole derivatives as possible antibacterial and antifungal agents, Farmaco, 54, 826–831 (1999)
  12. Silvestri R., Artico M., De Martino G., Ragno R., Massa S., Loddo R., Murgioni C., Loi A.G., LaColla P., and Pani A., Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5nitroimidazoles targeted at the HIV-1 reverse transcriptase, J. Med. Chem., 45, 1567–1576 (2002)
  13. Silvestri R., Artico M., Massa S., Marceddu T., DeMontis F. and LaColla P., 1-[2- (Diphenylmethoxy) ethyl]-2-methyl-5-nitroimidazole a potent lead for the design of novel NNRTIs, Bioorg. Med. chem. Lett., 10, 253-256 (2000)
  14. Hodgkiss R.J., Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia, Anticancer Drug Res. 13, 687–702 (1998)
  15. Hori H., Jin C.Z., Kiyono M., Kasai S., Shimamura M. and Inayama S., Design, synthesis, and biological activity of anti-angiogenic hypoxic cell radiosensitizer haloacetylcarbamoyl-2-nitroimidazoles, Bioorg. Med. chem., , 591–599 (1997)
  16. Kasai S., Nagasawa H., Yamashita M., Masui M., Kuwasaka H., Oshodani T., Uto Y., Inomata T., Oka S., Inayamata S. and Hori H., New antimetastatic hypoxic cell radiosensitizers: design, synthesis, and biological activities of 2nitroimidazole-acetamide and its analogues, Bioorg. Med. chem., , 453–464 (2001)
  17. Petray P.B., Morilla M.J., Corral R.S., Romero E.L., In vitro activity of Etanidazole against the protozoan parasite Trypanosoma cruzi,Memorias Instituto Oswaldo Cruz journal, 99, 233-235 (2004)
  18. Maeda K., Osata T., Umezawa H., A new antibiotic, azomycin, J. Antibiot., , 182 (1953)
  19. Al-Dabagh I.I., Mohammad F.K., Pharmacokinetics and distribution of metronidazole administered intraperitoneally in mice, Pharmacologyonline, 858–863 (2008)
  20. Tally F.P., Sutter V.L., Flnegold S.M., Treatment of anaerobic infections with metronidazole, Antimicrob. Agents Chemother., , 672–675 (1975)
  21. Goldring J., McNaught W., Scott A. and Gillespie G., Prophylactic oral antimicrobial agents in elective colonic surgery, A controlled trial, Lancet, , 997–1000 (1975)
  22. Tiwari P., Singh D. and Singh M.M., Anti-trichomonas activity of Sapindussaponins, a candidate for development as microbicidal contraceptive, J. Antimicrob. Chemotherapy, 62, 526–534 (2008)
  23. Upcroft P. and Upcroft J.A., Drug targets and mechanisms of resistance in the anaerobic protozoa, Clin. Microbiol. Rev., 14, 150–164 (2001)
  24. Atia A.J.K., Synthesis and antibacterial activities of new metronidazole and imidazole derivatives, Molecules, 14, 2431–2446 (2009)
  25. Sisson G., Goodwin A., Raudonikiene A., Hughes N.J., Mukhopadhyay A.K., Berg D.E. and Hoffman P.S. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother46, 2116–2123 (2002)
  26. Hoffman J.S. and Caves D.R., Treatment of Helicobacter pylori.Curr. Opin. Gastroenterol, 17, 30–34 (2001)
  27. World Health Organization, WHO model list of essential medicines, 15th edition, Available: http://www. who.int/medicines/ publications/EssMedList15.pdf. (2013)
  28. Baines S.D., O’Connor R., Freeman J., Fawley W.N., Harmanus C., Mastrantonio P., Kuijper E.J., Wilcox M.H., Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J. Antimicrob. Chemother., 62, 1046–1052 (2008)
  29. Viode C., Bettache N., Cenas N., Krauth-Siegel R.L., Chauviere G., Bakalara N., PerieJ., Enzymic reduction studies of nitroheterocycles, Biochem. Pharmacol., 57, 549–557 (1999)
  30. Thapa P.B., Whitlock J.A., Brockman K.G., Gideon P., Mitchel E.F., Roberson P., Pais R., Ray W.A., Prenatal exposure to metronidazole and risk of childhood cancer: A retrospective cohort study of children younger than 5 years, Cancer,83, 1461–1468 (1998)
  31. Meingassner J.G., Mieth H., Czok R., Lindmark D.G. and Muller M., Assay conditions and the demonstration of nitroimidazole resistance in Tritrichomonas foetus,Antimicrob. Agents Chemother., 13, 1–3 (1978)
  32. Britz M.L. and Wilkinson R.G., Isolation and properties of metronidazole-resistant mutants of Bacteroides fragilis, Antimicrob. Agents Chemother, 16, 19–27 (1979)
  33. http://en.wikipedia.org/wiki/Tinidazole (2013)
  34. Girginkardeler N., Cokun S., Cüneyt Balciolu I., Ertan P., Ok U.Z., Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole, Clin. Microbiol. Infect., 9(2), 110–113 (2003)
  35. De Backer E., Dubreuil L., Brauman M., Acar J. and Vaneechoutte M., In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis, Clin. Microbiol. Infect. 16 (5), 470–472 (2009)
  36. Rutgeerts P., Van Assche G., Vermeire S. et al., Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial, Gastroenterology, 128 (4), 856–61 (2005)
  37. Wayne, L. G.; Sramek, H. A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 38, 2054–2058 (1994)
  38. Agrawal K.C., Bears K.B., Sehgal R.K., Brown J.N., Rist P.E., Rupp W.D., Potential radiosensitizing agents dinitroimidazoles, J. Med. Chem, 22, 583–586 (1979)
  39. Nagarajan K., Shankar R.G., Rajappa S., Shenoy S.J. and Costa-Pereira R., Nitroimidazoles XXI. 2,3-Dihydro-6-nitroimidazo[2,1-]oxazoles with antitubercular activity, Eur. J. Med. Chem., 24, 631–633 (1989)
  40. Ashtekar, D. R.; Costa-Perira, R.; Nagrajan, K.; Vishvanathan, N.; Bhatt, A. D.; Rittel, W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis, Antimicrob. Agents Chemother., 37, 183–186 (1993)
  41. Stover, C. K.; Warrener, P.; Van Devanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis, Nature, 405, 962–966 (2000)
  42. New tuberculosis therapeutics: A growing pipeline, http:// www.tballiance.org/newscenter/view-brief.php? (2013)
  43. Edwards D.I., Nitroimidazole drugs--action and resistance mechanisms, I. Mechanisms of action, J. Antimicrob. Chemother.,31, 9 (1993)
  44. Edwards DI. Reduction of nitroimidazoles in vitro and DNA damage, Biochem Pharmacol., 35, 53 (1986)
  45. Müller M. Reductive activation of nitroimidazoles in anaerobic microorganisms, Biochem Pharmacol., 35, 37 (1986)
  46. Tocher JH, Edwards DI. The interaction of reduced metronidazole with DNA bases and nucleosides, Int. J. Radiat. Oncol. Biol. Phys., 22, 661(1992)
  47. Tocher JH, Edwards DI. Evidence for the direct interaction of reduced metronidazole derivatives with DNA bases, Biochem Pharmacol., 48, 1089 (1994)
  48. Goldman P, Koch RL, Yeung TC, et al. Comparing the reduction of nitroimidazoles in bacteria and mammalian tissues and relating it to biological activity, Biochem Pharmacol., 35, 43 (1986)
  49. Stratton CW, Weeks LS, Aldridge K.E., Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group, Diagn Microbiol Infect Dis., 14, 377 (1991)
  50. Stratton C.W., Weeks L.S. and Aldridge K.E., Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group, Diagn Microbiol Infect Dis., 15, 321 (1992)
  51. Ravdin JI, Skilogiannis J. In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole, Antimicrob. Agents Chemother, 33, 960 (1989)
  52. Nix DE, Tyrrell R, Müller M. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis, Antimicrob. Agents Chemother., 39, 1848 (1995)
  53. Ralph ED, Kirby WM. Unique bactericidal action of metronidazole against Bacteroides fragilis and Clostridium perfringens,Antimicrob. Agents Chemother 8, 409 (1975)
  54. Mohammad Hassan Moshafi, Maedeh Sorkhi, Saeed Emami, Maryam Nakhjiri, Azadeh Yahya-Meymandi, Amir Soheil Negahbani, Farideh Siavoshi, Maryam Omrani,Eskandar Alipour, Mohsen Vosooghi, Abbas Shafie, Alireza Foroumadi. 5-Nitroimidazole-based 1,3,4-Thiadiazoles: Heterocyclic Analogs of Metronidazole as Anti-Helicobacter pylori Agents. Arch. Pharm. Chem. Life Sci., 11, 178–183 (2011)
  55. Wen-Jun Mao, Peng-Cheng Lv, Lei Shi, Huan-Qiu Li, Hai-Liang Zhu. Synthesis, molecular docking and biological evaluation of metronidazole derivatives as potent Helicobacter pylori urease inhibitors, Bioorg. Med. Chem., 17, 7531–7536 (2009)
  56. Yong Qian, Hong-Jia Zhang, Hao Zhang, Chen Xu, Jing Zhao, Hai-Liang Zhu. Synthesis, molecular modeling, and biological evaluation of cinnamic acid metronidazole ester derivatives as novel anticancer agents Bioorg, Med. chem. Lett., 18, 4991–4996 (2010)
  57. Beena, Kumar Nitin, Rohilla Rajesh K., N. Roy, Rawat Diwan S. . Synthesis and antibacterial activity evaluation of metronidazole–triazole conjugates, Bioorg. Med. chem. Lett., 19, 1396–1398 (2009)
  58. Javier Giglio, Soledad Fernandez, Ana Rey, Hugo Cerecetto. Synthesis and biological characterisation of novel dithiocarbamate containing 5-nitroimidazole 99mTc-complexes as potential agents for targeting hypoxia. Bioorg. Med. chem. Lett., 21, 394–397 (2011)
  59. Massimo Bertinaria, Ubaldina Galli,Maria Immacolata Brenciaglia,Giovanni Sorba,Roberta Fruttero,Maria Maddalena Scaltrito, Alberto Gasco, Francesco Dubini. Synthesis and Anti-Helicobacter pylori Properties of NO-Donor/Metronidazole Hybrids and Related compounds, Drug Dev. Res,60, 225–239 (2003)
  60. Seref Demirayak, Ahmet Çagri Karaburun, Nuri Kiraz. Synthesis and antibacterial activities of some 1-[2(substituted pyrrol-1-yl)ethyl]-2-methyl-5-nitroimidazole derivatives, Eur. J. Med. Chem, 34, 275-278 (1999)
  61. Lalit Kumar, Amit Sarswat, Nand Lal, Vishnu L. Sharma, Ashish Jain, Rajeev Kumar, Vikas Verma, Jagdamba P. Maikhuri, Awanit Kumar, Praveen K. Shukla, Gopal Gupta. Imidazole derivatives as possible microbicides with dual protection, Eur. J. Med. Chem.,45, 817–824 (2010)
  62. Haythem A. Saadeh, Ibrahim M. Mosleh, Mustafa M. ElAbadelah. New Synthesis and Antiparasitic Activity of Model 5-Aryl-1methyl-4-nitroimidazoles, Molecules, 14, 2758-2767 (2009)
  63. Abdul Jabar Kh. Atia, Synthesis and Antibacterial Activities of New Metronidazole and Imidazole Derivatives, Molecules, 14, 2431-2446 (2009)
  64. Haythem A. Saadeh, Ibrahim M. Mosleh. Synthesis and antimicrobial activity of new 1,2,4-triazole-3-thiol metronidazole derivatives, Monatsh Chem , 141, 471–478 (2010)
  65. Kumar Lalit, Jain Ashish, Nand Lal, Sarswat Amit, Jangir Santosh, Kumar Lokesh, Singh Vishal, Shah Priyanka, Jain Swatantra K., Maikhuri Jagdamba P., Mohammad I. Siddiqi, Gupta Gopal, and Sharma Vishnu L., Potentiating Metronidazole Scaffold against Resistant Trichomonas: Design, Synthesis, Biology and 3D-QSAR Analysis, ACS Med. Chem. Lett., 3, 83-87 (2012)
  66. Mohammad Abid, Subhash M. Agarwal, Amir Azam, Synthesis and antiamoebic activity of metronidazole thiosemicarbazone analogues, Eur. J. Med. Chem., 43, 2035-2039 (2008)